Clinical trials: Post Discharge
Hypertension
Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
- Trial name
- NCT00861016
- Testing
- metoprolol succinate prolonged-release tablet and felodipine
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
The purpose of this study is to compare the steady-state pharmacokinetics of paliperidone after oral administration of 15 mg extended-release (ER) OROS paliperidone once daily with the steady-state pharmacokinetics of…
- Trial name
- NCT00796185
- Testing
- Paliperidone ER
- Volunteers
- 62 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV-I
Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629
The purpose of this study is to compare the bioavailability (the degree to which a drug becomes available in the body after administration) of 3 different pharmaceutical preparations of a combination of two drugs, TMC114 and…
- Trial name
- NCT00854204
- Testing
- TMC114; TMC41629
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Postmenopausal Osteoporosis
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00541658
- Testing
- risedronate
- Where
- 45 sites in United States, Argentina and 6 more
- Volunteers
- 923 people
- Sponsor
- Warner Chilcott
Depressive Disorder
A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects
The study was designed to assess the steady-state pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release tablet formulation (25 mg) in healthy Chinese subjects.
- Trial name
- NCT00406432
- Testing
- Paroxetine Controlled Release Tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Post Herpetic Neuralgia
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
- Trial name
- NCT01270828
- Testing
- Pregabalin
- Where
- 146 sites in United States, Bulgaria and 15 more
- Volunteers
- 806 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Decompensated Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
The purpose of this observational study is to collect and characterize multiple physiologic data from a broad subset of subjects with acute heart failure (HF) Changes in physiologic data are expected to correlate with 30-day…
- Trial name
- READMIT-HF (NCT01574144)
- Testing
- AVIVO™ PiiX Patch Monitor System
- Where
- 8 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Attention Deficit Disorder With Hyperactivity
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit…
- Trial name
- NCT01060150
- Testing
- OROS Methylphenidate HCl
- Volunteers
- 115 people
- Sponsor
- Janssen Korea, Ltd., Korea
Healthy Participants
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of PF-06700841 following single and multiple oral doses as modified release (MR) formulations in healthy, adult participants under fasted…
- Trial name
- NCT04580797
- Testing
- PF-06700841 IR, PF-06700841 MR1, PF-06700841 MR2
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state…
- Trial name
- NCT02273557
- Testing
- Asasantin ER (new formulation I - low), Asasantin ER (new formulation III - medium), Asasantin ER (new formulation II - high)
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Post-ischemic Stroke
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
- Trial name
- MILESTONE℠ (NCT02422940)
- Testing
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Where
- 66 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Acorda Therapeutics
Pain, Cancer
A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients…
- Trial name
- NCT00446069
- Testing
- Morphine Sulphate
- Where
- 8 sites in Lithuania, Poland
- Volunteers
- 36 people
- Sponsor
- Egalet Ltd
Cancer Abdomen
Epione® Post-Market Clinical Follow-up Study
Post-Market Clinical Follow-up study in order to consolidate performance and safety data of the EPIONE® device when used for percutaneous procedures in the abdomen
- Trial name
- SaFE (NCT05529979)
- Testing
- EPIONE® CT-Guided Percutaneous procedures
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Quantum Surgical
Attention Deficit Hyperactivity Disorder
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
- Trial name
- NCT00564954
- Testing
- Dex-methylphenidate hydrochloride extended-release (Focalin XR)
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)
- Trial name
- NCT02273531
- Testing
- Asasantin ER, new formulation, Asasantin ER, present commercial formulation
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Crohn Disease
A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
Crohn's Disease (CD) is a chronic pathology characterized by exacerbations and remissions. Recurrent inflammation can cause bowel strictures, fistulae (often perianal) or abscesses. CD often requires intestinal resection.
- Trial name
- STOP-PER (NCT03537157)
- Testing
- Rifaximin delayed release tablets
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Alfasigma S.p.A.
Pain
Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars
This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo-controlled efficacy study to evaluate the efficacy and safety of 2×300mg ibuprofen Prolonged Release (PR) tablets…
- Trial name
- NCT03785756
- Testing
- Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Aortic Valve Stenosis, Aortic Valve Insufficiency
Enable® Aortic Sutureless Bioprosthesis Evaluation
The EASE Enable study is intended to collect additional data on the clinical outcomes of the Medtronic Enable® Aortic Bioprosthesis in "real world" patients.
- Trial name
- EASE (NCT01720342)
- Testing
- Aortic Valve Replacement surgery
- Where
- 17 sites in France, Germany and 5 more
- Volunteers
- 225 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cardiac Electrophysiology
Transvenous Lead Removal Post-Market Clinical Study
This prospective, multicenter, post-market clinical study was designed to evaluate the outcomes of lead extraction of cardiovascular implantable electronic devices (CIED) using Cook catheter and lead extraction devices for any…
- Trial name
- NCT03688412
- Testing
- Cook lead extraction devices
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Cook Research Incorporated